Is Privia Health Group, Inc. overvalued or undervalued?

As of 24 October 2025, the valuation grade for Privia Health Group, Inc. moved from very expensive to fair. The company appears to be overvalued, particularly when considering its P/E ratio of 181, which is significantly higher than peers like Globe Life, Inc. at 11.82 and Primerica, Inc. at 12.59. Additionally, the EV to EBITDA ratio of 82.17 and the Price to Book Value of 4.29 further highlight the premium at which Privia is trading compared to its industry counterparts.
In terms of performance, Privia Health Group has shown strong returns, with a year-to-date return of 32.94%, significantly outperforming the S&P 500's 15.47%. However, over the three-year period, the company has underperformed with a return of -19.34% compared to the S&P 500's 78.85%. This mixed performance, alongside its high valuation ratios, suggests that while the stock may have short-term appeal, it is fundamentally overvalued in the context of its financial metrics.